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INTRODUCTION
The outcome following a diagnosis of colorectal cancer is directly related to the stage at diagnosis, with over 90% of those who undergo resection for Stage 1 disease alive at 5-years compared with less than 50% for Stage III disease [1] . Independent of the TNM stage, however,there are other additional adverse features of the tumour itself and the patient, the so called 'host ' , that have been shown to predict a worse outcome. For example, the presence of venous invasion or poor differentiation, are now used in clinical practice to help identify patients with more aggressive Stage II disease who are at a higher risk and hence may benefit from adjuvant chemotherapy [2] [3] [4] . It has been argued recently that the combination of T-stage and venous invasion is superior to the traditional TNM stage in predicting outcome in node negative disease [5] .
There is now a wealth of evidence that the presence of an elevated host systemic inflammatory response (SIR) is an independent negative prognostic factor in patients with cancer [6] . The SIR can be assessed routinely with standard bedside tests such as C-reactive protein (CRP) or the neutrophil to lymphocyte ratio (NLR) [7] [8] [9] [10] [11] . In the case of colorectal cancer specifically, those with an elevated pre-operative SIR have a poorer outcome independent of the TNM stage [7, 12] .
What does this paper add to the literature?
In addition to having tumours of an earlier stage, patients with tumours detected through the FOBt screening programme have improved host prognostic factors, in terms of a lower preoperative systemic inflammation response, than patients with non screen-detected disease.
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Screening for colorectal cancer using the guaiac-based faecal occult blood test (gFOBt) increases the number of early stage cancers diagnosed and reduces cancer specific mortality [13] [14] [15] . In addition, there is increasing evidence that screening using the faecal immunochemical test (FIT) may have improved sensitivity over gFOBt [16] [17] [18] . This has lead to the development of the Scottish Bowel Screening Programme (SBoSP), which is a combined gFOBt/FIT population based screening programme [19] . This has been found to detect a large number of early stage tumours, although interval cancers (tumours that develop within two years of a negative screening test) do develop [20] .
In assessing the efficacy of colorectal cancer screening, previous work has examined differences between screen-detected and non screen-detected disease and has shown improved survival in screen-detected patients [21] [22] [23] [24] [25] [26] [27] . Such analysis has, however, focused on the stage and site of tumours and only one such study has included detailed analysis of adverse tumour factors beyond TNM stage that are of independent prognostic significance [21] . Furthermore, to date, no previous studies have included assessment of the pre-operative host systemic inflammatory response within the context of a colorectal cancer screening programme. The aim of the present study was to examine the efficacy of the first round of a population based gFOBt/FIT colorectal cancer screening programme in our geographical area with regard to cancer detection rates, and to compare and contrast adverse tumour and host prognostic factors in screen-detected and non screen-detected colorectal cancer. 
METHOD
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This article is protected by copyright. All rights reserved. Individual patient records were then interrogated on a case-by-case basis to identify further clinicopathological variables for analysis. Tumours were staged according to the conventional tumour node metastasis (TNM) classification (5 th Edition) [28] . Polyp cancers that were managed endoscopically, and did not undergo formal resection were assumed to be node negative and classified as TNM Stage I. Additional high-risk tumour features, such as poor
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Both the absolute neutrophil count and the neutrophil to lymphocyte ratio (NLR) were used as markers of the pre-operative SIR and were obtained from pre-operative blood results taken most immediately and not more than six weeks before surgery. A previously validated threshold of an NLR of >5 was used as evidence of a significantly elevated SIR [9] . An absolute neutrophil level greater than 7.5 x 10 9 /litre was defined as elevated based on local laboratory guidelines.
Permission for the study was granted by the Caldicott Guardian of the Screening dataset and by the West of Scotland Colorectal Cancer MCN Management group. Data were stored and analysed in an anonymised manner.
Statistical analysis
Associations between categorical variables were examined using the χ 2 test. For ordered variables with multiple categories the χ 2 test for a linear trend was used. Fisher's exact test was used for assessing associations where the expected individual cell counts were less than 5. A value of p<0.05 was considered statistically significant. Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA) 
RESULTS
From
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Comparison of Screen-detected and Non Screen-detected Colorectal cancer
SD patients were more likely than NSD patients to be male (p=0.002), have more distal disease (p=0.003), which was of an earlier stage (p<0.001) and were more likely to undergo a procedure with a curative intent (p<0.001) ( Table 1) . In those undergoing a curative procedure, SD patients had a less advanced T-stage and less evidence of venous invasion, peritoneal involvement and margin involvement (p<0.05). They also had less evidence of an elevated preoperative SIR judged by the NLR and the absolute neutrophil count (Table 2) . A stage by stage analysis of factors was then carried out (Supplementary Table 2 ). Patients with SD tumours had less evidence of an elevated SIR in stage II and III disease. There was no significant difference in venous invasion rates between SD and NSD tumours in all four stages (Supplementary Table 2 ).
Comparison of Interval and Screen-detected Cancers
INT patients were more likely than SD patients to be female (p<0.001), have more proximal disease (p<0.001), have more advanced disease (p<0.001) and less likely to be managed with a curative intent (p<0.001) ( Table 3 ). In addition, they were more likely to have adverse prognostic factors such as venous invasion (p=0.026) and an elevated pre-operative SIR (p=0.025) ( 
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Comparison of Interval and Non-Responder Cancers
INT patients were more likely than NR patients to be female (p=0.034) ( Table 4 ). There was trend towards INT patients having less advanced (p=0.052) and more proximal disease (p=0.090) but this did not reach significance at the 5% level. When patients who were treated with a curative intent were examined, there was no difference in adverse pathological features between INT and NR patients. There was a trend for NR patients have an elevated preoperative SIR (p=0.059) compared with INT patients (Table 4) .
DISCUSSION
The results of the present study provide a comprehensive analysis of the outcome from the first round of a stool-based colorectal cancer screening programme. It confirms previous studies that have found that screen-detected tumours are of an earlier stage than non screen-detected tumours and reports for the first time that individuals with screen-detected disease have more favourable host prognostic factors than those with non screen-detected disease.
Analysis of host factors, such as the presence of an elevated SIR has not previously been examined within the context of a colorectal cancer screening programme. In addition to inflammatory responses in the tumour micro-environment [30] , systemic inflammatory responses are now recognised as a key hallmark of cancer [6] . In particular there is a wealth of evidence that host factors are associated with an adverse outcome in colorectal cancer including meta-analyses [7, 11] . To date, however, their inclusion as a means of predicting outcome outside in the routine clinical setting has been patchy. In the present study the most readily available measure of the systemic inflammatory response, in the form of neutrophils and the neutrophil to lymphocyte ratio has been included [31, 32] . This additional information adds to the level of detail available for the cohort and is a unique feature of this comprehensive analysis.
It could be argued that the present study, showing that some adverse tumour prognostic factors are less prevalent in SD tumours than in NSD tumours, is evidence for the effect of length-time bias where the identification of indolent slow growing tumours artificially improves cancerspecific survival by detecting those who have a longer pre-clinical phase [33] . When, however, adjustment is made for stage, the two key features in keeping with phenotypically more aggressive tumours, venous invasion and poor differentiation, do not achieve statistical significance. Furthermore, it has previously been postulated that INT tumours not only represent tumours missed by the screening test itself but may be more aggressive if they develop within the screening interval [20] . Examining in detail tumour and host prognostic factors in INT compared with NR tumours provides evidence to refute this hypothesis. There was no evidence of adverse tumour features in the INT group when compared with the NR group in the present study. Indeed, there was a trend for NR patients to have evidence of a higher host SIR. Therefore, the conclusion that can be drawn from the present study is that the inherent biological characteristics of SD tumours do not differ from those of NSD disease.
There were higher numbers of cancers in both the NA and CN groups than initially expected. On further investigation, however, it became apparent that a substantial proportion of the NA patients (40%, data not presented), were already under investigation for colorectal symptoms and had sent back the screening test in the midst of undergoing non-screening investigations. Also, of the 15 patients who were CN, 12 (80%) (data not presented) had polyps detected at colonoscopy and hence were undergoing follow-up. For the purposes of the present study, a cancer diagnosis outwith six months of initial colonoscopy was defined as NSD, but it may be argued that these patients would not have been detected at that time had they not participated in screening. Nevertheless, the 15 patients who were CN represent a post-colonoscopy colorectal cancer rate of 3% which compares favourably with other studies that have examined this outwith screening programmes which have provided rates of 2-8%, albeit with longer (3 to 5 year) follow-up [34] [35] [36] . The majority of post-colonoscopy colorectal cancers are thought to arise through procedural factors such as missed lesions and inadequate examination [35] . The
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SBoSP has tight quality control on all colonoscopists requiring to be Joint Advisory Group (JAG) accredited and have a greater than 90% caecal intubation rate [37] . It was not in the scope of the present study to examine colonoscopy quality indexes in more detail, but the low rate of post-colonoscopy colorectal cancer was reassuring.
Strengths and weaknesses
The main strengths of the present study include the comprehensive and detailed dataset. Case notes were examined on a case-by-case basis allowing for more detailed analysis of clinicopathological factors at a depth that has not previously been undertaken. For example, in the present study after case note review, only 2% of tumours remained unstaged compared with 25% in a previous study using population databases [23] . In addition, we have included data from non-responders, which have been absent from other studies, and by utilising regional and national cancer registry datasets we have comprehensively captured those with NSD disease from corroborative sources.
The main limitation of the study is the fact that this is a prevalence round of a screening programme and as such these results may not be applicable in subsequent rounds. This is important when analysing data presented regarding sensitivity and specificity. A further possible limitation was that all NSD tumours were taken as the main comparison group.
Comparing INT to SD tumours might have been a better measure of the impact of screen detection. Nevertheless the present study represents a population setting whereby compliance to the screening programme was just over 50%. Therefore to exclude NR tumours, would be to exclude from the study a large proportion of the population invited for screening. A subanalysis comparing SD with INT tumours was undertaken and no difference in prognostic factors was elicited when adjusted for stage. Such subanalyses will by definition be limited by reduced numbers and hence power and additional work is required to examine these findings further.
Finally, our measure of the SIR was by NLR and not the modified Glasgow Prognostic Score
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(mGPS), which has been shown to be a more sensitive measure of host inflammation with regard outcome [8] , but this is a retrospective study, and C-reactive protein required for calculating mGPS, was not routinely measured pre-operatively in all hospitals during this timeframe.
In conclusion, the present study reports that patients with SD tumours, independent of stage, had more favourable host prognostic factors than patients with NSD tumours. There was, however, no difference in adverse tumour features associated with an aggressive tumour phenotype. In addition, INT cancers did not appear to have more aggressive features than tumours that developed in the rest of the population and hence were more likely to arise as a result of the limitations of the testing algorithm itself rather than represent biologically more aggressive tumours. Further work, identifying a more sensitive test is required to increase the number of tumours that are detected through screening and hence to improve the outcome in colorectal cancer.
